High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder.
about
Intravesical electromotive drug administration for non-muscle invasive bladder cancerIntravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancerComparison of Guidelines on Non-Muscle Invasive Bladder Cancer (EAU, CUA, AUA, NCCN, NICE)Diagnosis of narrow-band imaging in non-muscle-invasive bladder cancer: a systematic review and meta-analysisUpdate on the management of non-muscle invasive bladder cancer.Canadian guidelines for treatment of non-muscle invasive bladder cancer: a focus on intravesical therapy.Clinical outcome of primary versus secondary bladder carcinoma in situA Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients.Clinical outcomes of primary bladder carcinoma in situ in a contemporary seriesBest practice in the treatment of nonmuscle invasive bladder cancer.Complication of treatment of carcinoma in situ of the bladder with photodynamic targeted cystodiathermyOncolytic viruses in the treatment of bladder cancerCUA guidelines on the management of non-muscle invasive bladder cancer.A prospective comparison of intra-arterial chemotherapy combined with intravesical chemotherapy and intravesical chemotherapy alone after transurethral resection with a thulium laser in high-risk non-muscle invasive bladder cancer.Recent improvements in the detection and treatment of nonmuscle-invasive bladder cancer.Superficial bladder cancer: part 1. Update on etiology, classification and natural history.Superficial bladder cancer: part 2. Management.Survival from bladder cancer in England and Wales up to 2001.The current classification of urothelial neoplasms.Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladderMicroRNA Expression Profile Identifies High Grade, Non-Muscle-Invasive Bladder Tumors at Elevated Risk to Progress to an Invasive PhenotypeBacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer.Intravesical therapy for urothelial carcinoma of the bladder.High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment.Follow-up procedures for non-muscle-invasive bladder cancer: an update.Photodynamic diagnosis for follow-up of carcinoma in situ of the bladder.Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group.Early Stage Bladder Cancer: Do Pathology Reports Tell Us What We Need to Know?Urethral carcinoma in situ: recognition and management.Guideline of guidelines: non-muscle-invasive bladder cancer.The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer - A New Analysis.Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.Conservative management and female gender are associated with increased cancer-specific death in patients with isolated primary urothelial carcinoma in situ.Identification of BLCAP as a novel STAT3 interaction partner in bladder cancer.Outpatient photodynamic-guided diagnosis of carcinoma in situ with flexible cystoscopy: an alternative to conventional inpatient photodynamic-guided bladder biopsies in the operating theatre?Prognostic value of renin-angiotensin system blockade in non-muscle-invasive bladder cancer.Intravesical electromotive drug administration for non-muscle invasive bladder cancer.Safe and effective administration of BCG for bladder carcinoma in situ after umbilical cord blood stem cell transplantation.Implementing risk-aligned bladder cancer surveillance care.Progression to T1 High Grade (T1HG) from a Lower Stage/Grade is Associated with Poorer Survival Outcomes than Initial Diagnosis with T1HG Bladder Cancer.
P2860
Q24187574-7FB0E8E9-7674-440A-BEEC-61787295A2C8Q24234614-514D0CFA-DB5B-40AB-BEF4-FEB52F46D79BQ26744756-33478FAE-118B-4F20-93CF-E2BB74CD91DCQ26859123-E7195934-9E99-49DA-852F-E439C93F638CQ33613070-D4136868-1691-4413-BA88-85AA3CA087D5Q33869233-F2B64B8C-BBD7-4C02-8318-4639A1BC74DCQ34205568-9E8F1543-750D-47CF-AFBE-0D01DB8A6CA7Q34389519-BCF510C0-A1CF-4519-8AEA-48A22443C598Q34480396-E2FCF892-6B16-4293-9B84-6DB294D0DA8FQ35688392-630F7328-665C-494C-AB96-93038C607E51Q35758393-826AE037-A074-48DE-921F-A36442A6E1E1Q36147934-B832F40C-21FD-410A-927E-9CB3F430DF04Q36326208-B9259DDD-F480-40B0-9D6E-3A3810AD5334Q36350505-228DF620-713F-4743-B274-01E33AA67B42Q36614005-B7FCD78F-59D8-4C0A-97D8-5E816454600FQ36689131-FC5A7547-CAA5-4F35-8C84-0AD963660863Q36788508-94629293-D7BD-4202-AFFD-FD2186F621A3Q36917745-007A11F3-0E85-4846-8059-C3D8626AEC56Q37507537-D88A5523-F62C-4696-806B-4E80B10E097BQ37635650-A7E8F9B3-C027-4B32-BB4E-3FF93EF968D9Q37676257-FC46F32A-6FC5-44DF-913A-ADF1A64DE27EQ37811051-8B98B125-B4D2-46A2-AD0D-D795EE66A1BBQ37911278-A7963C87-9924-42B3-BABC-7B49454D1B89Q38052445-C3F5045B-B4E6-4712-AF31-8B7F14D2476CQ38055500-B29A1323-116C-4E16-BC8A-CB03A732D33AQ38535982-782A7D7A-ED7E-4B2F-A63D-291BB310B8A6Q38711963-E055E3C7-670E-4639-B275-5109D75F384BQ38824831-663DE65C-B7AC-4F46-8C8E-5870C93D683CQ39013320-F2401163-C94D-42FA-ADE0-EC8EB1EF62F2Q39069660-4B351724-AD75-42F3-B7D4-9421FBCDB39CQ39634006-67BB479D-4332-424A-875F-0E1A5E357AE2Q42361547-3ADD75BA-729E-4F90-9556-A58320F7485BQ44508630-B7FC860C-42E3-4BB4-B254-A1458455D682Q47099158-70E87C83-8741-4053-9E70-BEEDB2CB5026Q47270100-C3F3EB12-A529-482C-840F-F8ECC366B1CAQ47292033-980827FB-D9D9-4913-B8CD-0DB60908B6A1Q47997127-BE12431F-E040-4519-BBE4-0C0463FEAFF9Q48258318-C39B9CC6-D651-4233-87EF-FCD8408319FBQ48507562-5695DAC9-B23C-4F1B-9CD8-6415A06808A0Q50611751-9CB55D31-D58B-494C-8A5F-9D7C0E0020AE
P2860
High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder.
@ast
High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder.
@en
type
label
High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder.
@ast
High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder.
@en
prefLabel
High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder.
@ast
High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder.
@en
P2093
P1433
P1476
High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder.
@en
P2093
Aaron Torres
Adrian van der Meijden
Chris Cheng
Gerhard Jakse
J A Witjes
Karl Heinz Kurth
Norio Nonomura
Richard J Sylvester
Roger Watson
P304
P356
10.1016/J.UROLOGY.2005.06.135
P407
P433
P577
2005-12-01T00:00:00Z